Targeting transcription factors for therapeutic benefit.
Transcription factors are a large class of biological molecules that are important for health and disease. Despite that there are challenges to targeting them therapeutically and most approaches alter their activity indirectly. Research at the chemical biology interface has led to the development of new ways of targeting transcription factors including blocking transcription factor dimerisation, targeting specific DNA sequences and DNA decoys. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of cancer.
Brennan
Paul
P
Medical Biochemistry & Immunology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK. BrennanP@cardiff.ac.uk
Donev
Rossen
R
Hewamana
Saman
S
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry*; D001483:Base Sequence; D004247:DNA / Q000378:metabolism; D019281:Dimerization; D006801:Humans; D008954:Models, Biological; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D009447:Neuroblastoma / Q000188:drug therapy / Q000378:metabolism; D021381:Protein Transport; D012097:Repressor Proteins / Q000378:metabolism; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000099229:RE1-Silencing Transcription Factor
D000970:Antineoplastic Agents; D004247:DNA; D016328:NF-kappa B; D012097:Repressor Proteins; D014157:Transcription Factors; D000099229:RE1-Silencing Transcription Factor